Skip to content
    UNH
    Earnings call· Dec 2024(Q4 FY24)

    UNITEDHEALTH GROUP INC UNH

    Jan 16, 2025 Source

    Executive summary

    UnitedHealth Group Q4 FY24 — Strong FY24 Delivery Amid Challenges, Confident FY25 Outlook

    UnitedHealth Group delivered solid Q4 FY24 results, meeting its adjusted EPS outlook despite significant headwinds including Medicare rate cuts, Medicaid redeterminations, and the Change Healthcare cyberattack. The company is confident in its FY25 outlook, driven by strategic portfolio adjustments, strong Medicare Advantage AEP performance, and continued digital transformation efforts aimed at improving efficiency and consumer experience. Management also committed to 100% PBM rebate pass-through to clients by 2028.

    Highlights

    5

    • FY24 revenues exceeded $400 billion and adjusted earnings per share reached $27.66, both within the initial outlook ranges.

    • Optum Health revenues grew to $105 billion in 2024 and are expected to approach $117 billion in 2025.

    • Optum Rx achieved customer retention exceeding 98% and welcomed a record 750 new clients in 2024.

    • UnitedHealthcare grew to serve 2.4 million more people in domestic commercial offerings in 2024.

    • Strong Medicare Advantage AEP results are expected to drive growth of up to 800,000 people in 2025.

    Concerns

    4

    • The FY24 medical care ratio was 150 basis points above the original outlook, creating a nearly $5 billion gap.

    • The Change Healthcare cyberattack resulted in a nearly $1 billion business disruption impact in 2024.

    • A more-rapid-than-expected acceleration in high-cost medication prescribing and aggressive hospital coding intensity contributed to the MLR increase in 2024.

    • Optum Health's consumer count dropped by approximately 4 million due to strategic deemphasis of certain offerings like urgent care.

    Guidance & targets

    10
    CategoryTargetConfidence
    Optum Health Revenue
    approach $117 billion
    high materiality
    High
    Optum Health Value-Based Care Patients
    about 5.4 million
    medium materiality
    High
    Optum Rx Revenue
    about $146 billion
    high materiality
    High
    Optum Insight Revenue
    approach $22 billion
    medium materiality
    High
    UnitedHealthcare Revenue
    approach $340 billion
    high materiality
    High
    UnitedHealthcare Additional People Served
    upwards of an additional 1.9 million people
    high materiality
    High
    UnitedHealthcare Medicare Advantage Growth
    up to 800,000 people
    high materiality
    High
    Medical Care Ratio
    86.5%
    high materiality
    High
    Cash Flow from Operations
    approach $33 billion
    high materiality
    High
    Long-Term Growth Objective
    13% to 16%
    high materiality
    High

    Segment performance

    4
    SegmentRevenueYoYQoQMargin
    Optum Health
    Revenues grew to about $105 billion in 2024 and are expected to approach $117 billion in 2025. The business is deepening its presence and expanding into new geographies and services. Strategic initiatives include reshaping the business post-V28, restructuring legacy contracts, and investments in clinical quality and the STARS program. Consumer count dropped by 4 million due to deemphasis of certain narrow offerings like urgent care.
    Value-based care patients (2025): 5.4 millionValue-based care patient growth (2025 vs 2024): 650,000In-home patient visits resulting in primary care visit within 90 days: >75%Value-based patient engagement (overall): 85%Value-based patient engagement (highest risk): 90%
    		$105 billion———
    Optum Rx
    Revenues grew to over $130 billion in 2024 and will be about $146 billion in 2025. Achieved strong customer retention and welcomed a record number of new clients. Committed to fully phasing out arrangements that do not pass through 100% of rebates to clients by 2028.
    Customer retention: >98%New clients: 750New consumers served (Jan 1, 2025): 1.6 millionNew client onboarding cost reduction: 33% YoYDigital engagement registrations: +16%
    		$130 billion———
    Optum Insight
    Revenues were $19 billion in 2024 and will approach $22 billion in 2025. Backlog stands at $35 billion as sales of new products take hold and the customer clearinghouse business rebuilds. Solutions aim to improve consumer experience and payment/claims flows.
    Backlog: $35 billion
    		$19 billion———
    UnitedHealthcare
    Full year revenues approached $300 billion in 2024 and will approach $340 billion in 2025. Grew to serve 2.4 million more people in domestic commercial offerings in 2024, with continued strong growth expected in self-funded offerings. Medicare Advantage growth was impacted in 2024 by unusual benefit designs, but strong AEP results for 2025 are expected to drive growth of up to 800,000 people in individual, group, and special needs offerings, with near record retention.
    Additional people served (2025): upwards of 1.9 millionDomestic commercial people served growth (2024): +2.4 millionMedicare Advantage growth (2025): up to 800,000 peopleUHC mobile app visits growth: +66% YoYUHC app registrations growth: nearly +100% YoYOverall digital engagement growth: +33% YoYPhone calls reduction: -10% annually
    		approached $300 billion———

    Operational metrics

    7
    Adjusted EPS
    $27.66within outlook ranges
    FY24

    Well within the outlook ranges set out over a year ago.

    Operating cost ratio improvement
    150over prior year
    FY24

    Improved about 150 basis points over the prior year, with roughly half from business portfolio initiatives and the other half from accelerating operating efficiencies.

    Growth capital deployed
    $17 billion
    FY24

    Deployed nearly $17 billion in growth capital to help build for the future.

    Shareholder returns
    $16 billion
    FY24

    Returned over $16 billion to shareholders through dividends and share repurchase.

    PBM rebate pass-through
    >98%
    FY24

    Last year, our PBM passed through more than 98% of the rebate discounts we negotiated with drug companies to our clients.

    PBM rebate pass-through commitment
    100%
    by 2028

    Committed to fully phasing out remaining arrangements, so that 100% of rebates will go to customers by 2028 at the latest.

    Claims rejected for clinical reason
    <0.5%
    current

    Less than half of 1% of claims are ultimately rejected for clinical reason.

    Industry KPIs

    7
    MetricValueDetails
    Utilization trendsmore-rapid-than-expected accelerationdirectional
    Stars rate environmentpreliminarystatus
    Medical loss care ratio86.5%%
    Client retention new wins>98%%
    Membership covered lives by lineupwards of an additional 1.9 million peoplepeople
    Adjusted EPS EBITDA leverage guidance$27.66USD
    Medical cost trend vs pricing assumptioncommensurate with what we saw in '24directional

    Deals & partnerships

    1
    GeorgiaAwarded new opportunity for Medicaid services.

    UnitedHealthcare was honored to have been awarded a new opportunity in Georgia for Medicaid services, indicating expansion in the public sector.

    Risks & headwinds

    6
    CMS Medicare rate cutsFY24, FY25

    first year of the 3-year CMS Medicare rate cuts (2024); second year of the Medicare funding cuts (2025)

    Mitigation: Undertook initiatives and made investments to strengthen for the future, optimizing portfolio.

    Medicaid member redeterminationsFY24

    effects of the state-driven Medicaid member redeterminations

    Mitigation: Outlook assumes a measured pacing of the gap narrowing between people's health status and state rates; actions to date, including the January 1 renewal cycle, support this view.

    Change Healthcare cyberattackFY24

    nearly $1 billion in business disruption impact

    Mitigation: Undertook initiatives and made investments to strengthen for the future, optimizing portfolio.

    Elevated medical care ratio (MLR)FY24

    150 basis points above original outlook (FY24), creating a nearly $5 billion gap

    Mitigation: Strategic adjustments to MA benefit designs, focus on self-funded commercial offerings, strong AEP results for '25 with high retention and uptake of managed offerings.

    Rapid acceleration in high-cost medications and hospital coding intensityFY24

    more-rapid-than-expected acceleration in the prescribing of certain high-cost medications; aggressive upshift in hospital coding intensity

    Mitigation: Incorporated into '25 outlook, working to get it back in line. PBM efforts to negotiate lower drug prices.

    Pharmaceutical drug pricingOngoing

    GLP-1 costs $900 in U.S. vs 1/10 in Europe

    Mitigation: PBMs play vital role in holding prices down; OptumRx delivers tens of billions in savings. Commitment to 100% rebate pass-through to clients by 2028.

    What to watch in Q1 FY25

    5

    Medicaid state rate updates and health status gap

    Over the course of FY25
    CurrentGap between people's health status and state rates narrowing
    TargetContinued narrowing and measured pacing of the process

    Why it matters

    Impacts Medicaid segment profitability and growth, particularly after redetermination activities.

    In Medicaid, we see the gap between people's health status and state rates narrowing over the course of the year. Our outlook assumes a measured pacing of that process. Actions to date, including the important January 1 renewal cycle, support this view.

    Q&A highlights

    6

    Were there any changes in the intensity of cost trends or unusual items impacting Q4 MLR, and does management remain confident in the 2025 MLR outlook?

    John Rex confirmed Q4 cost trends (hospital coding intensity, specialty prescribing) were in line with Q3, not accelerating, and were anticipated in the 2025 outlook. He noted that 80-90 basis points of the Q4 MLR impact came from non-run rate revenue effects like group MA refunds, and 50-60 basis points from seasonal flu/RSV. Andrew Witty reiterated confidence in 2025 pricing and mix.

    “Nothing we saw there that changes our view of '25. We feel very good about how we priced into '25. We feel really good about how the mix has come in, in terms of that growth. That's a huge difference to '24.”

    asked by Albert Rice · answered by Andrew Witty

    2 min read6 chapters

    Detailed Narrative

    01

    FY24 Performance and Overcoming Challenges

    Despite unforeseen challenges in 2024, including the first year of CMS Medicare rate cuts, state-driven Medicaid member redeterminations, and the Change Healthcare cyberattack, UnitedHealth Group delivered revenues over $400 billion and adjusted EPS of $27.66, within its initial outlook. The company undertook initiatives and made investments totaling nearly $17 billion to strengthen for the future, optimizing its portfolio and enhancing consumer experience to overcome approximately $6 billion in unanticipated impacts.

    02

    Medical Care Ratio Dynamics and FY25 Confidence

    The FY24 medical care ratio (MCR) was 150 basis points above the original outlook, primarily due to a different consumer profile in Medicare Advantage, timing mismatch in Medicaid health status and state rates, costs from the cyberattack, and South America business impacts. Additionally, a rapid acceleration in high-cost medication prescribing and aggressive hospital coding intensity contributed. Management expressed confidence in its 2025 pricing, with an expected MCR of 86.5% (plus or minus 50 basis points), incorporating care activity levels seen in 2024 and supported by strong Medicare Advantage AEP results.

    03

    Operating Cost Efficiency and Digital Transformation

    The 2024 operating cost ratio improved by 150 basis points over the prior year, with half attributed to business portfolio initiatives and the other half to accelerating operating efficiencies. Early impacts from AI-driven initiatives are improving customer service, with 10% fewer phone calls annually and UHC mobile app visits up 66% year-over-year. Further improvements in operating costs are expected in 2025 and beyond as digital adoption and modernization efforts continue to scale.

    04

    PBM Reform and Rebate Transparency Commitment

    Addressing concerns around PBM practices, UnitedHealth Group committed to fully phasing📎 out arrangements that do not pass through 100% of rebates to clients, aiming for complete pass-through by 2028. This move is intended to increase transparency and highlight that drug companies are primarily responsible for high drug prices. Optum Rx currently passes through over 98% of negotiated rebates and delivers tens of billions in annual savings.

    05

    Strategic Evolution of Optum Health

    Optum Health is reshaping its business post-V28, focusing on direct patient engagement, medical management, and integrating operations for efficiency. This includes deemphasizing certain narrow offerings like standalone urgent care, which contributed to a 4 million drop in consumer count, and making investments in clinical quality and the STARS program. The segment expects to serve about 5.4 million value-based care patients in 2025, a growth of 650,000 over 2024.

    06

    UnitedHealthcare Growth and Market Position

    UnitedHealthcare's full-year revenues approached $300 billion in 2024 and are expected to approach $340 billion in 2025, serving an additional 1.9 million people. The domestic commercial offerings grew by 2.4 million people in 2024, with continued strong growth expected in self-funded offerings. Despite Medicare Advantage growth being impacted in 2024 by unusual benefit designs, strong AEP results for 2025 are expected to drive growth of up to 800,000 people, with high retention and a significant number of returning members.

    AI-generated summary of the company’s earnings call. Not investment advice.